PspA and PspC: their potential for use as pneumococcal vaccines.
about
Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New AntimicrobialsMolecular basis of host specificity in human pathogenic bacteriaDiversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.Adhesins as targets for vaccine development.Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremiaIntranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.Characterization of binding of human lactoferrin to pneumococcal surface protein AGenetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniaePneumococcal virulence factors: structure and functionRegulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae.Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniaeRethinking recommendations for use of pneumococcal vaccines in adults.Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniaePneumococcal vaccination and revaccination of older adults.Pathogenesis of A Clinical Ocular Strain of Streptococcus pneumoniae and the Interaction of Pneumolysin with Corneal Cells.Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention.Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniaeDistribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers.Species-specific interaction of Streptococcus pneumoniae with human complement factor H.PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniaeA modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4.Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae.Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsisPneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clonesInactivation of the srtA gene affects localization of surface proteins and decreases adhesion of Streptococcus pneumoniae to human pharyngeal cells in vitro.PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].Analysis of Spleen-Induced Fimbria Production in Recombinant Attenuated Salmonella enterica Serovar Typhimurium Vaccine Strains.CRH Affects the Phenotypic Expression of Sepsis-Associated Virulence Factors by Streptococcus pneumoniae Serotype 1 In vitro.Molecular characterization of pneumococcal surface protein K, a potential pneumococcal vaccine antigen.Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniaeDevelopment of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences.
P2860
Q26744448-E395B4D6-E371-4205-9EEE-3210D684FDA0Q26864388-4C530D74-0467-419E-A92E-3A7BE46D8283Q33592652-918747ED-00C5-4440-838D-2F32192D45C2Q33643106-5530EBED-E86F-4F43-AD23-422704951658Q33975380-F1F13074-AA5F-497F-9593-29612C277B4FQ33997738-E2533455-4F58-45CE-B7FC-CD54B69BB44BQ34002787-43E8C863-D19D-4241-A6AB-6D703D27CCF3Q34003306-3A4F0921-7B22-4A65-9748-BB1F5B3F120CQ34005995-74B4EBF8-D61D-413A-83B2-099F69E20DCDQ34007403-F9113DF9-A706-4EFC-BC5D-B912A2E91616Q34008890-15A9759F-7CA4-41F7-A11D-27F1F2D03EB5Q34010335-05BE0663-CE19-4858-8640-0AD9C3E39E0EQ34110032-D650D84F-E68A-436A-8706-B8C6CD1FAD7CQ34121334-5BDADC80-9D46-4644-BEF2-35820CF1FAAEQ34326459-CF8CA8AC-0453-4A2F-8378-E372304074C3Q34530684-8967DA49-1612-4D05-A8F4-8C44E7AD9296Q34926870-A546FFC8-1015-41F6-A9A6-98B8925AB715Q35651831-4A438BDE-2442-4EF1-81F8-19D814715DD2Q36228991-41F132E6-CD2C-4D97-9C3B-23FFF86CE1ACQ36257961-0370AABD-5206-418D-89E7-0425C037A459Q36933011-00133D21-D69A-4735-8535-E00EB05C5076Q36933015-9691DB1B-476D-47E5-A0E6-2E610C4C9C58Q36984721-46EAE58E-BAAD-4C63-89AD-0670DCEA0E7AQ37355855-3D9CF28C-41CD-41E6-A8E5-7B84F161F21FQ37483596-ED4EEFA5-CC25-4FB4-B1B5-4DF778D7E5B0Q38350313-AFBB0D39-14BE-44FA-BACA-DA0383A25773Q38486051-8E83DF7C-F60E-41B0-83FF-163FA6D63960Q39023214-C3E05B84-0E59-42F4-B169-542BD1B1A879Q39461608-83A59929-3B9E-45D1-9281-5F1B7135DCB9Q39746150-DAAC77EA-A9B9-48B2-BF53-6D707808AA14Q40014811-C3F2CDF6-5C88-4A07-BA2D-B1566B083313Q40083818-DC4C1737-194D-4E05-91C2-AC8A43956015Q40142223-6C25E2EA-A9EE-4134-9F7D-4A6D9EB6A988Q40383072-065AE57F-4DB5-44F1-A663-38A2E27823B7Q41938147-C3C7B3AC-3A47-4D7D-8435-BA0E1D3D390FQ54349086-66A9C4F1-8CB7-4029-8055-FB190396E2F3
P2860
PspA and PspC: their potential for use as pneumococcal vaccines.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
PspA and PspC: their potential for use as pneumococcal vaccines.
@en
type
label
PspA and PspC: their potential for use as pneumococcal vaccines.
@en
prefLabel
PspA and PspC: their potential for use as pneumococcal vaccines.
@en
P2093
P356
P1476
PspA and PspC: their potential for use as pneumococcal vaccines.
@en
P2093
Brooks-Walter A
Hermansson A
Hollingshead SK
McDaniel LS
Prellner K
P304
P356
10.1089/MDR.1997.3.401
P577
1997-01-01T00:00:00Z